Stallergenes inaugurates new headquarters in France.
Antony (France), 2011-may Stallergenes S.A. opened its new financial and administrative headquarters in Antony (France).
after the official opening of its production plant pollen in Amilly (Loiret, France Department) recently, Stallergenes opened on 24 May its new headquarters administrative and financial in a ceremony attended by Patrick Devedjian, French parliamentarian and President of the Council General of the Department of Hauts-de-Seine, and Dr. Isao TeshirogiPresident and Chief Executive Officer of Shionogi & Co. Lt, strategic ally of Stallergenes in Japan, and President of the Japan Association of pharmaceutical manufacturers (JPMA).
started in 2009 and designed to meet the highest standards of high environmental quality (HQE) and low consumption of energy (BBC), the new building will house more than 200 employees and will allow the company to increase the space available for r & d.
enjoying an average annual growth of 14% – the sector has grown in comparison a 5% – Stallergenes has quadrupled its size in the last ten years and is currently the seventh largest pharmaceutical France. Stallergenes has invested the fruits of this growth in research and development of new products, with an investment of accumulated since 2004 of EUR 170 million and 30 million invested in new facilities. The company spends about 20% of its annual profits in r & d, sum of € 41 million in 2010 and becoming one of the top ten pharmaceutical companies in France, in terms of investment.
between 2001 and 2011, the number of group employees increased from 400 to 1,000, and 300 to 750 in Antony. Only in 2010, the number of employees of the group grew 12%, half of them being staff highly qualified (at least 5 years of higher education).
our growth has allowed Stallergenes follow a business model based on innovation. our shareholders have supported this model, whereby profits are reinvested in the company. As an example of this expansion, the headquarters of Antony, which houses all of our structural decisions has grown significantly in a few years, with the permanent assistance of the city of Antony and the Department of Hauts-de-Seine ”, said Albert Saporta, President and Chief delegate of Stallergenes.
with operations in 10 countries, soon will be opened 5 new branches, so Stallergenes performs at present about 85% of their business in Europe. In parallel, the company signed an exclusive agreement for collaboration with Shionogi & Co. Ltd., one of the largest pharmaceutical companies of Japan, in September 2010. The purpose of this agreement is the development and commercialization of two tablets of sublingual immunotherapy of Stalair ® program: compressed for dust mites and pollen from Cedar Japanese. are delighted to have found a strategic partner to strengthen our position in the market of products for allergy in Japan in Satllergenes ”, said Isao Teshirogi, President and Chief Executive Officer of Shionogi & Co., Ltd.
Stallergenes is proof that it is possible to succeed in France by combining innovation and industry. Our role is to create the conditions for this work ”, said Patrick Devedjian.
on the Stalair ® program.
Stalair ® is the program for pharmaceutical and clinical of sublingual immunotherapy tablets development developed by Stallergenes to obtain marketing authorization as proprietary medicinal products in Europe and other markets strategic.
released in 2003 in line with the directives issued in 2009 by the European Medicines Agency (EMA), the program offers the same level of recognition that the pharmaceutical standard for tablets of immunotherapy.
Oralair ® is the first capsule for the program. Marketed since 2008 in Germany, was launched recently in Spain, Netherlands, Czech Republic, Slovakia, Austria and Italy. It is in the process of being authorized and marketed in other countries.
the second project in the program are the tablets of sublingual immunotherapy against dust mites. Its effectiveness has been recently demonstrated after four months of treatment and the permanence of its effect after only a year of treatment (study VO57.07 in Europe). Stallergenes is currently preparing documentation for registration to obtain the approval in Germany and has begun a phase III study with children. After consultations with the German governing biological products Agency (PEI), Stallergenes shall submit to the German authorities the documentation plans necessary for the registration of authorisation during the present year. Stallergenes to commercialize these sublingual tablets in Germany at the end of 2012, and in Europe in 2013 through the procedure of recognition mutual.
the compressed with rBet v1 (recombinant of birch pollen allergen) has been tested in a study of Phase IIb/III, with positive results in to Birch pollen allergic rhinitis. Additional studies are currently being developed. The tablets for ragweed pollen and Japanese cedar pollen are in the early stages of development.
in its entirety, the program covers 80% of allergy breathing in all the markets of immunotherapy.
about Stallergenes.
Stallergenes S.A. is a biopharmaceutical company international, a leader in the manufacture and innovation of allergen immunotherapy treatments. Stallergenes sells its products to prevent and control the allergic disease in 50 countries by more than 10 subsidiaries in Europe and 40 agreements of distribution and collaboration around the world.
Stallergenes in Antony (Ãle-de-France) factory is the largest center of production of allergens prepared specially for a patient (APEP) in the world, making more than 150 allergens different to treat each year some 500,000 patients.
more than 20% of the annual pharmaceutical company business figure is intended for research and development…
Stallergenes Ibérica S.A. is the subsidiary of Stallergenes S.A. in our country has one portfolio of products for the treatment of 95% of patients affected by respiratory allergic diseases and has been, since its implementation in Spanish territory for 11 years, by a strong work of research into new products.
